BA
TEVA icon

Bivin & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Bivin & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-55
Closed – – 421
2021
Q4 		$0 Buy
+55
New +$496 ﹤0.01% 408

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Bivin & Associates's TEVA Position: Q1 2022 in Review

Bivin & Associates sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 55 shares.

Bivin & Associates first reported a position in TEVA in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • Bivin & Associates reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Bivin & Associates sold 55 Teva Pharmaceuticals shares in Q1 2022.
  • Bivin & Associates first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Bivin & Associates's Teva Pharmaceuticals position peaked at $0 in Q4 2021.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on Bivin & Associates's 13F filing for Q1 2022, filed 6 May 2022.